Neonatal Abstinence Syndrome Tied to Poor School Performance

Share this content:
Neonatal Abstinence Syndrome Tied to Poor School Performance
Neonatal Abstinence Syndrome Tied to Poor School Performance

MONDAY, Jan. 16, 2017 (HealthDay News) -- Children with neonatal abstinence syndrome (NAS) may be more likely to perform poorly in school, according to a new study published online Jan. 16 in Pediatrics.

The study included 2,234 children born with NAS in New South Wales, Australia, between 2000 and 2006. The researchers based their results on tests given in third, fifth, and seventh grades. They compared the children with NAS with a control group of 4,330 children unaffected by the syndrome. Both groups were matched for socioeconomic status, gender, and time spent in the womb. The test results were also compared with those of 598,265 other New South Wales children.

Test scores for children with NAS, on average, were sharply lower than those of both groups of children. By seventh grade, their scores were lower than those of fifth-grade children. The researchers also found that 37.7 percent of these seventh graders failed to meet test standards in at least one of the tested areas.

"These drugs cause brain cells to die more quickly and impair their proper development," lead author Ju-Lee Oei, M.D., a senior neonatologist at the Royal Hospital for Women in New South Wales, told HealthDay. Families affected by addiction also may be more "socially chaotic," the study authors said. "Early intervention and support for both the mothers and their children have been shown to be extremely effective in high-risk populations, and the benefits can extend for decades and even into generations," Oei said.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »